bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.

bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies

Bluebird Bio (BLUE) stock is diving on Tuesday after announcing a suspension of some of its clinical trials due to safety concerns. The post BLUE Stock Alert: Why Bluebird Bio Shares Are Plunging Today appeared first on InvestorPlace.

BLUE Stock Alert: Why Bluebird Bio Shares Are Plunging Today

Shares of bluebird bio Inc (NASDAQ: BLUE) were sinking Tuesday morning following an adverse clinical pipeline development. What Happened: Cambridge, Massachusetts-based Bluebird said it has placed the Phase 1/2 and Phase 3 clinical studies of its LentiGlobin gene therapy in sickle cell disease on a temporary suspension.

Bluebird Bio Temporarily Suspends Sickle Cell Gene Therapy Studies Following Incidences of Blood Cancer

Bluebird Bio temporarily suspended all studies of a sickle cell disease gene therapy on Tuesday — prompting BLUE stock to collapse. Shares hit a seven-year low in early trading.

Bluebird Stock Collapses To 7-Year Low On Safety Concern In Gene Therapy

LOS ANGELES--(BUSINESS WIRE)---- $BLUE #BLUE--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Shares of Bluebird Bio Inc. slid 34% in premarket trade Tuesday, after the biotech said it is temporarily suspending Phase 1/2 and Phase 3 trials of its LentiGlobin gene therapy for sickle cell disease after a report of a suspected unexpected serious adverse reaction of acute myeloid leukemia. The patient involved was treated more than five years ago and has not been diagnosed with AML, the company said in a statement.

Bluebird Bio shares slide 34% after company suspends trials of sickle cell disease treatment

Atlanta, Georgia--(Newsfile Corp. - February 16, 2021) -  Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) securities between May 11, 2020 and November 4, 2020, inclusive (the "Class Period"). The complaint alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA...

SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of bluebird bio Investors and Encourages Investors With Significant Losses to Contact the Firm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that the company has placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML). In line with the clinical study protocols for HGB-206 and HGB-210, bluebird bio placed the studies on temporary suspension following a

bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)

NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) in the United States District Court for the Eastern District of New York on behalf of those who purchased or acquired the securities of bluebird between May 11, 2020 and November 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for investors under the federal securities laws.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (BLUE)

LOS ANGELES--(BUSINESS WIRE)---- $BLUE #BLUE--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2021. SO WHAT: If you purchased bluebird securities during the Class Period you

BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – BLUE

PHILADELPHIA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) ( NASDAQ: BLUE ) to determine whether the Company engaged in securities fraud or other unlawful business practices.

Have You Invested In bluebird bio, Inc.? - Class Action Lawsuit Filed On Behalf Of BLUE Investors – Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.

NEW YORK--(BUSINESS WIRE)-- #bluebirdbio--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of investors that purchased bluebird bio, Inc. (NASDAQ: BLUE) securities between May 11, 2020 and November 4, 2020, inclusive (the “Class Period”). Investors have until April 13, 2021 to apply to the Court to be appointed as lead plaintiff in the law

BLUEBIRD BIO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its officers. The class action, filed in the United States District Court for the Eastern...

Pomerantz Law Firm Announces the Filing of a Class Action against bluebird bio, Inc. and Certain Officers - BLUE

Amarin Corporation Plc

Nektar Therapeutics

These stocks have one obvious thing in common.

3 Stocks Wall Street Thinks Will Soar 50% or More in 2021

bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.

bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity

Bluebird Bio, Inc. (NASDAQ: BLUE) is a gene therapy company that focuses on treatments for severe genetic diseases and cancer.  Early investors that got in near the $25 level as part of Bluebird's 2013 IPO saw their holdings increase in value nearly eight-fold by 2015 only to give up the vast majority of the gains by 2016.

Bluebird Bio CEO talks business spinoff after a 47% loss in 2020

The biotech will then focus on its rare disease programs.

bluebird bio to Spin Off Its Oncology Business

Shares of Bluebird Bio Inc. gained 5.1% in premarket trading on Monday after it announced plans to spin off its oncology business as a separate publicly-traded company. Bluebird will retain its genetic disease business.

Bluebird's stock is up 5% as it details plans to separate oncology and genetic disease businesses

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly traded companies. bluebird bio, Inc. will retain focus on severe genetic disease (SGD) and will launch its oncology business (“Oncology Newco”) as a new entity. bluebird bio's Board of Directors approved the intent to separate into two companies and it is anticipated that the spin out of Oncology New

bluebird bio to Separate Oncology Business into Independent Company

bluebird had a rough 2020 but we are quickly approaching several key catalysts in 2021 that will transform the company's outlook and possibly inject some momentum into the share price. ZYNTEGLO has conditional approval in the EU for those with transfusion-dependent beta-thalassemia. The company is now taking aim at the pediatric and β0/β0 genotype indications.

bluebird bio: One Of My Top Picks For 2021

I estimate the fair value for BLUE between $5-7 billion based on similar acquisitions. 2021 could be an inflection point with the anticipated approval of the company's multiple myeloma treatment.

bluebird bio Inc., Undervalued Acquisition Candidate

Telesis Bio Inc

Editas Medicine

Big drugmakers could be attracted to these smaller players with promising pipelines.

3 Top Biotech Buyout Candidates in 2021

Biogen

TG Therapeutics

These biotech stocks could sink or soar following some important approval decisions slated for the new year.

News for bluebird bio Stock (BLUE)